Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Full IRB Study Title:
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
For complete details, please view the study on clinicaltrials.gov.
Study in conjunction with Cincinnati Children's Hospital.
Study Sponsor:
National Cancer Institute
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Erin Wright, MD
Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic
